PMID: 6166802Mar 1, 1981Paper

Cardiovascular properties of medroxalol, a new antihypertensive drug

Journal of Cardiovascular Pharmacology
R C DageJ K Woodward


Medroxalol is a new antihypertensive agent that is presently undergoing clinical trial. Its cardiovascular properties were studied using spontaneously hypertensive rats (SHR), anesthetized dogs, and isolated tissues. Medroxalol produced a long-lasting fall in blood pressure when given by the oral route to SHR. It was more potent than phentolamine in antihypertensive effectiveness. Given intravenously to dogs, medroxalol reduced the blood pressure and heart rate of doses that did not greatly reduce cardiac output. The hypotensive effect of medroxalol was reduced but not abolished following alpha- and beta-adrenergic-receptor blockade. Medroxalol inhibited heart rate and blood pressure responses to isoproterenol and phenylephrine in dogs. In vitro medroxalol resembled a competitive antagonist at alpha-adrenergic receptors in rabbit aortic strips (pA2 6.09) and beta-adrenergic receptors in guinea pig atria (pA2 7.73). It was 0.02 as potent as phentolamine at alpha-receptors and 0.09 as potent as propranolol at beta-receptors. It was concluded that the principal action of medroxalol was to produce a fall in blood pressure by decreasing peripheral vascular resistance more than cardiac output. Adrenergic alpha- and beta-receptor bloc...Continue Reading


Oct 1, 1987·American Heart Journal·B N Prichard, B Tomlinson
Jan 1, 1984·Clinical and Experimental Hypertension. Part A, Theory and Practice·A A Hancock
Jan 27, 1984·The American Journal of Cardiology·R M Graham
Oct 1, 1983·Journal of Clinical Pharmacology·N D VlachakisR F Maronde
May 1, 1984·British Journal of Clinical Pharmacology·H L ElliottJ L Reid
May 1, 1984·British Journal of Clinical Pharmacology·H L ElliottJ L Reid
Jan 1, 1987·Toxicologic Pathology·D M Sells, J P Gibson
Oct 1, 1983·Biopharmaceutics & Drug Disposition·F J KeeleyR A Okerholm
Mar 1, 1982·The Journal of Pharmacy and Pharmacology·J K Woodward, H C Cheng
Jan 1, 1986·British Journal of Clinical Pharmacology·B N Prichard, C W Owens
Jan 1, 1982·Acta Medica Scandinavica. Supplementum·K E Andersson

Related Concepts

Medroxalol monohydrochloride, (S-(R*, S*))-isomer
Antihypertensive Agents
Diastolic Blood Pressure
Cardiovascular System
Canis familiaris
Dose-Response Relationship, Drug
Cavia porcellus
Hypertensive Disease

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Risk Reduction

Prevention of cardiovascular disease is an important health initiative. Risk reduction including physical activity, smoking cessation, diet, blood pressure lowering drugs and pharmacotherapy. Here is the latest research on cardiovascular risk reduction.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

© 2021 Meta ULC. All rights reserved